Childhood Synovial Sarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Apart from the canonical SS18-SSX fusion, this is only the second alternative gene fusion variant described in synovial sarcoma to date, in addition to two cases harboring the SS18L1-SSX1 fusion.
|
31595587 |
2020 |
Childhood Synovial Sarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Interestingly, three SS18 fusion genes (SS18-SSX2B, SS18-SSX2, and SS18-SSX4) were identified in a synovial sarcoma case.
|
31232935 |
2019 |
Childhood Synovial Sarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The diagnosis of primary renal synovial sarcoma requires histopathology and the confirmation of SYT-SSX gene fusion using molecular techniques.
|
31367627 |
2019 |
Childhood Synovial Sarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We demonstrate that BRD9 supports oncogenic mechanisms underlying the SS18-SSX fusion in synovial sarcoma and highlight targeted degradation of BRD9 as a potential therapeutic opportunity in this disease.
|
30431433 |
2018 |
Childhood Synovial Sarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Additionally, we showed that SS can originate from periosteal cells expressing SS18-SSX alone and from preosteoblasts expressing the fusion oncogene accompanied by the added stabilization of β-catenin, which is a common secondary change in SS.
|
29202462 |
2018 |
Childhood Synovial Sarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The SS18-SSX Oncoprotein Hijacks KDM2B-PRC1.1 to Drive Synovial Sarcoma.
|
29502955 |
2018 |
Childhood Synovial Sarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Isobaric tags for relative and absolute quantitation (i-TRAQ) analyses identified approximate 1700-2,000 proteins regulated by the SS18/SSX fusion in each SS cell line.
|
30680066 |
2018 |
Childhood Synovial Sarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Epigenetic ConFUSION: SS18-SSX Fusion Rewires BAF Complex to Activate Bivalent Genes in Synovial Sarcoma.
|
29894696 |
2018 |
Childhood Synovial Sarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Meta-analyses showed that the test of detecting MDM2 amplification by fluorescence in situ hybridization was accurate in differentiating atypical lipomatous tumor/well-differentiated liposarcoma/dedifferentiated liposarcoma from benign tumors (N = 971; sensitivity = 95%, 95% confidence interval [CI] 89-98; specificity = 100%, CI 89-100) or from other STS (N = 347; sensitivity = 99%, CI 72-100; specificity = 90%, CI 78-95); that the test of detecting SS18-SSX fusion by reverse transcription polymerase chain reaction (PCR) was accurate in differentiating synovial sarcoma from other STS (N = 532; sensitivity = 93%, CI 85-96; specificity = 99%, CI 96-100).
|
29709714 |
2018 |
Childhood Synovial Sarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we demonstrate that SS18-SSX globally hijacks BAF complexes on chromatin to activate an SS transcriptional signature that we define using primary tumors and cell lines.
|
29861296 |
2018 |
Childhood Synovial Sarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This review summarises our current understanding of the function of SS18-SSX and the mechanisms by which it alters the epigenetic landscape of permissive cells to induce transformation and the subsequent development of synovial sarcoma.
|
30506527 |
2018 |
Childhood Synovial Sarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Immunoreactivity of a Monoclonal Antibody to SS18-SSX Fusion Gene Product in Formalin-fixed Paraffin-embedded Synovial Sarcoma Tissue Section.
|
27362474 |
2018 |
Childhood Synovial Sarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The aim of this study was to verify whether histological (grading and histology) and molecular (type of SSX translocation and INI1 expression) characteristics of SS influence the prognosis of the disease.
|
28579008 |
2017 |
Childhood Synovial Sarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The SS18-SSX chimeric gene is unique to synovial sarcoma.
|
29025595 |
2017 |
Childhood Synovial Sarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Synovial sarcoma is associated with a unique translocation, resulting in an SYT-SSX fusion gene.
|
27697479 |
2017 |
Childhood Synovial Sarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The prognostic impact of SYT-SSX fusion type and histological grade in pediatric patients with synovial sarcoma treated according to the CWS (Cooperative Weichteilsarkom Studie) trials.
|
27621063 |
2017 |
Childhood Synovial Sarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Fusion gene SYT-SSX may play a critical role in the molecular pathological of SS.
|
28498445 |
2017 |
Childhood Synovial Sarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Synovial sarcoma (SS) is initiated by a t(X;18) chromosomal translocation and resultant SS18-SSX fusion oncogene.Only a few SS cell lines exist.
|
28409421 |
2017 |
Childhood Synovial Sarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Synovial sarcoma (SS) is an aggressive soft-tissue malignancy characterized by expression of SS18-SSX fusions, where treatment options are limited.
|
29038346 |
2017 |
Childhood Synovial Sarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here, we show that SS18/SSX tightly regulates the elevated expression of the key Wnt target AXIN2 in primary SS.
|
26905812 |
2016 |
Childhood Synovial Sarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Three cases (1.5%) revealed the SYT-SSX transcript for Synovial sarcoma, and one (0.5%) a EWSR1-WT1 transcript for Desmoplastic Small Round Cell tumor.
|
27180056 |
2016 |
Childhood Synovial Sarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the present study, we examined the effects of the cellular context on the function of the synovial sarcoma (SS)-specific fusion protein, SS18-SSX, using human pluripotent stem cells (hPSCs) containing the drug-inducible SS18-SSX gene.
|
26571495 |
2015 |
Childhood Synovial Sarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We reviewed patients with localized SS; SS18-SSX fusion transcript presence was confirmed by FISH and RT-PCR.
|
25613038 |
2015 |
Childhood Synovial Sarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Proteomic studies have identified an integral role of SS18-SSX in the SWI/SNF complex, and provide new evidence for mistargeting of polycomb repression in synovial sarcoma.
|
25614489 |
2015 |
Childhood Synovial Sarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, there is significant morphologic heterogeneity and overlap with a variety of other neoplasms, which can cause diagnostic challenge, particularly as the immunoprofile is varied, SS18-SSX is not detected in 100% of SSs, and they may occur at unusual sites.
|
25438927 |
2014 |